SynthesisInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences2021
Bleomycin for orbital and peri-orbital veno-lymphatic malformations - A systematic review.
Synthesis in Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Percutaneous Bleomycin Sclerotherapy for Retroorbital Venous Malformations.Cardiovascular and interventional radiology · 2026Article
- Efficacy and safety of a navigation-assisted, multi-approach endoscopic surgical strategy for orbital apex cavernous hemangiomas.Frontiers in oncology · 2026Article
- Impact of Intracystic Hemorrhage on Therapeutic Outcomes in Macro/Mixed Cystic Lymphatic Malformation: A Retrospective Cohort Study.Children (Basel, Switzerland) · 2025Article
- The Oculocardiac Reflex: A Rare but Significant Cardiovascular Complication During Percutaneous Sclerotherapy of a Retro-Bulbar Low Flow Venolymphatic Malformation.Cardiovascular and interventional radiology · 2023Article
- Optical coherence tomography enhanced depth imaging of chorioretinal folds in patients with orbital tumors.International journal of ophthalmology · 2023Article
- Orbital Venolymphatic Malformation Treated With Sodium Tetradecyl Sulfate: A Case Report.Cureus · 2022Article
- Vascular lesions of the pediatric orbit: A radiological walkthrough.Frontiers in pediatrics · 2022Review
- Bleomycin for Percutaneous Sclerotherapy of Venous and Lymphatic Malformations: A Retrospective Study of Safety, Efficacy and Mid-Term Outcomes in 26 Patients.Journal of clinical medicine · 2021Article
- Classification, diagnosis, and management of orbital venous-lymphatic malformations: Current state-of-the-art.Taiwan journal of ophthalmologyReview
- The efficacy and safety of bleomycin injection as the primary management of orbital venolymphatic malformations: A systematic review.Oman journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrbital and peri-orbital venolymphatic malformations (VLM) are low flow vascular malformations. Intralesional bleomycin is now commonly being used to treat such malformations.
objectiveThe purpose of this systematic review is to synthesize evidence on the safety and efficacy of bleomycin/pingyangmycin sclerotherapy for the treatment of orbital and peri-orbital VLM.
methodsWe searched Medline, Embase, Scopus and Cochrane database for studies reporting outcomes of bleomycin/pingyangmycin sclerotherapy for orbital and peri-orbital VLM between 1974 to April 5th, 2019. Nine retrospective cohort studies enrolling 132 patients were included. Two reviewers independently screened and extracted data and assessed the risk of bias. Predefined outcome measures were subjective and objective reduction of the lesion and associated complications.
resultsSubjective reduction of the lesions was seen in 96.2% of the studies. Objective reduction of the lesion and symptomatic improvement were reported in 91.6 and 95% of the studies respectively. Non responders were 9.0%. Minor adverse events were reported in 18.1% of the studies. Major complications like pulmonary toxicity or pulmonary fibrosis was not encountered in any of the included studies. Quality of evidence was generally low.
conclusionBleomycin/pingyangmycin sclerotherapy is very effective and relatively safe for the treatment of orbital and periorbital VLM and is not associated with any major side effects including pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.